226 related articles for article (PubMed ID: 33218353)
1. Whether Letrozole could reduce the incidence of early ovary hyperstimulation syndrome after assisted reproductive technology? A systematic review and meta-analysis.
Zhao J; Xu B; Huang X; Yan Y; Li Y
Reprod Health; 2020 Nov; 17(1):181. PubMed ID: 33218353
[TBL] [Abstract][Full Text] [Related]
2. Aromatase inhibitors for subfertile women with polycystic ovary syndrome.
Franik S; Kremer JA; Nelen WL; Farquhar C
Cochrane Database Syst Rev; 2014 Feb; (2):CD010287. PubMed ID: 24563180
[TBL] [Abstract][Full Text] [Related]
3. The role of Letrozole (LE) in controlled ovarian stimulation (COS) in patients at high risk to develop ovarian hyper stimulation syndrome (OHSS). A prospective randomized controlled pilot study.
Tshzmachyan R; Hambartsoumian E
J Gynecol Obstet Hum Reprod; 2020 Feb; 49(2):101643. PubMed ID: 31563697
[TBL] [Abstract][Full Text] [Related]
4. Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial.
Mai Q; Hu X; Yang G; Luo Y; Huang K; Yuan Y; Zhou C
Am J Obstet Gynecol; 2017 Jan; 216(1):42.e1-42.e10. PubMed ID: 27555316
[TBL] [Abstract][Full Text] [Related]
5. Dopamine agonists for preventing ovarian hyperstimulation syndrome.
Tang H; Mourad S; Zhai SD; Hart RJ
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD008605. PubMed ID: 27901279
[TBL] [Abstract][Full Text] [Related]
6. Prednisone combined with letrozole reduced risk of ovarian hyperstimulation syndrome (OHSS) in women undergoing long-term gonadotropin-releasing hormone analog treatment.
Fang L; Ruan M; Yang S; Qu X; Chen H; Zhao J; Cheng J
Ann Palliat Med; 2021 Aug; 10(8):8837-8847. PubMed ID: 34488372
[TBL] [Abstract][Full Text] [Related]
7. Cabergoline for preventing ovarian hyperstimulation syndrome.
Tang H; Hunter T; Hu Y; Zhai SD; Sheng X; Hart RJ
Cochrane Database Syst Rev; 2012 Feb; (2):CD008605. PubMed ID: 22336848
[TBL] [Abstract][Full Text] [Related]
8. [Letrozole versus gonadotropin-releasing hormone antagonist during luteal phase in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial].
Cheng ZX; Kong G; Zhang CL; Zhao YN
Zhonghua Fu Chan Ke Za Zhi; 2020 Jan; 55(1):9-14. PubMed ID: 32074767
[No Abstract] [Full Text] [Related]
9. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
[TBL] [Abstract][Full Text] [Related]
10. Effect of GnRH-antagonist, mifepristone and letrozole on preventing ovarian hyperstimulation syndrome in rat model.
Luo J; Qi Q; Chen Y; Wang Y; Xie Q
Reprod Biomed Online; 2021 Feb; 42(2):291-300. PubMed ID: 33249057
[TBL] [Abstract][Full Text] [Related]
11. [Luteal letrozole administration decreases serum estrogen level but not the risk of ovarian hyperstimulation syndrome].
Wang YQ; Yang J; Xu WM; Xie QZ; Yan WJ; Yin TL; Cheng D; Xiao ZN; Li J
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Dec; 45(6):869-72. PubMed ID: 24343064
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcome.
Luke B; Brown MB; Morbeck DE; Hudson SB; Coddington CC; Stern JE
Fertil Steril; 2010 Sep; 94(4):1399-1404. PubMed ID: 19591989
[TBL] [Abstract][Full Text] [Related]
13. Effects of different doses of letrozole on the incidence of early-onset ovarian hyperstimulation syndrome after oocyte retrieval.
He Q; Liang L; Zhang C; Li H; Ge Z; Wang L; Cui S
Syst Biol Reprod Med; 2014 Dec; 60(6):355-60. PubMed ID: 25192259
[TBL] [Abstract][Full Text] [Related]
14. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
[TBL] [Abstract][Full Text] [Related]
15. The impact of letrozole on oocyte quality in assisted reproductive technology (ART); a randomized double-blind clinical trial.
Hossein Rashidi B; Shahrokh Tehraninejad E; Amanpour S; Bandarian F; Bandarian M
Gynecol Endocrinol; 2022 Dec; 38(12):1087-1092. PubMed ID: 36562249
[TBL] [Abstract][Full Text] [Related]
16. Does the additional use of clomiphene citrate or letrozole for in vitro fertilization deserve more attention?
Liang Y; Guo Q; Wu XH; Zhang LN; Ge J; Xu ML; Feng ZL; Wu XQ
BMC Pregnancy Childbirth; 2021 Apr; 21(1):275. PubMed ID: 33794797
[TBL] [Abstract][Full Text] [Related]
17. Ovarian hyperstimulation syndrome: a clinical retrospective study on 565 inpatients.
Du DF; Li MF; Li XL
Gynecol Endocrinol; 2020 Apr; 36(4):313-317. PubMed ID: 31429334
[TBL] [Abstract][Full Text] [Related]
18. First-line ovulation induction for polycystic ovary syndrome: an individual participant data meta-analysis.
Wang R; Li W; Bordewijk EM; Legro RS; Zhang H; Wu X; Gao J; Morin-Papunen L; Homburg R; König TE; Moll E; Kar S; Huang W; Johnson NP; Amer SA; Vegetti W; Palomba S; Falbo A; Özmen Ü; Nazik H; Williams CD; Federica G; Lord J; Sahin Y; Bhattacharya S; Norman RJ; van Wely M; Mol BW; ;
Hum Reprod Update; 2019 Nov; 25(6):717-732. PubMed ID: 31647106
[TBL] [Abstract][Full Text] [Related]
19. Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials.
Leitao VM; Moroni RM; Seko LM; Nastri CO; Martins WP
Fertil Steril; 2014 Mar; 101(3):664-75. PubMed ID: 24360566
[TBL] [Abstract][Full Text] [Related]
20. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline.
;
Fertil Steril; 2016 Dec; 106(7):1634-1647. PubMed ID: 27678032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
